ClinicalTrials.gg
CompletedNCT02948582Updated Mar 12, 2018Results posted

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Glycopyrrolate Inhalation Solution12.5μg and Glycopyrrolate Inhalation Solution 50μg in Chronic Obstructive Pulmonary Disease, sponsored by Sunovion Respiratory Development Inc.. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-12.

Sponsored by Sunovion Respiratory Development Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
40 Years to 75 Years
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Sumitomo Pharma Co., Ltd..

Enrollment
20th of 24
42 · median 225
Started
2010
the only one that year
Phase 2
7 of 24
none open now
Registered
22nd of 24
by date

Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 20th largest by enrollment, is the only one that started in 2010, is one of 7 in phase 2, and was the 22nd registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd. as a file.
02

Study summary

The study assessed the safety and ability of an orally inhaled medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered using an eFlow nebulizer in 42 patients with Chronic Obstructive Pulmonary Disease (COPD). Each patient randomly received several, single doses of GIS, or placebo, separated by approximately 1 to 2 weeks. After the dose was given, lung airflow was measured over 24 hours and blood was collected to measure how much GIS was in the bloodstream. The study was conducted to find the once-a- day GIS dose that produced the highest improvement in lung airflow using the eFlow nebulizer.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic Obstructive Pulmonary Disease
  • COPD
  • Emphysema
  • Chronic bronchitis
04

Who can participate

Ages eligible
40 Years to 75 Years
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 40 through 75 years, inclusive
  2. A clinical diagnosis of according to the GOLD guidelines
  3. Current smokers or ex-smokers with at least 10 pack-year smoking history (e.g., at least 1 pack/day for 10
  4. Post-bronchodilator 30-70% of predicted normal at the Screening Visit
  5. Post-bronchodilator FEV1/FVC ratio \< 0.70 at the Screening Visit
  6. Improvement in FEV1 >12% and 150 mL following inhalation of ipratropium bromide at the Screening Visit
  7. Ability to perform reproducible spirometry according to the ATS/ERS guidelines
  8. Willing to stay at the study site for approximately 30 hours on each treatment visit
  9. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or lactating at the Screening Visit, or if of not using one of the following acceptable means of throughout the study:

    • Abstinence
    • for at least two years
    • Surgically sterile (i.e., tubal ligation, hysterectomy)
    • Oral contraceptives (taken for at least one month prior to the Screening Visit)
    • Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent)
    • Barrier methods (e.g., condoms with spermicide)
    • Intrauterine device (i.e., IUD)
    • Vasectomy of male partner
    • Non-heterosexual life style
  2. Current evidence or recent history of any disease (other than ) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data; including but not limited to cardiovascular disease, myocardial infarction, cardiac failure, uncontrolled hypertension, life-threatening arrhythmias, uncontrolled diabetes, neurologic or neuromuscular disease, liver disease, gastrointestinal disease or electrolyte abnormalities
  3. Recent history of hospitalization due to an exacerbation of airway disease within 3 months or need for increased treatments for COPD within 6 weeks prior to the Screening Visit
  4. Primary diagnosis of asthma
  5. Prior lung volume reduction surgery or history of chest/lung irradiation
  6. Regular use of daily oxygen therapy
  7. Use of systemic (eg, intramuscular or intravenous) within 3 months prior to the Screening Visit
  8. Respiratory tract infection within 6 weeks prior to the Screening Visit
  9. History of tuberculosis, bronchiectasis or other non- specific pulmonary disease
  10. History of urinary retention or bladder neck obstruction type symptoms
  11. History of narrow-angle glaucoma
  12. Clinically significant abnormal
  13. Positive surface antigen or positive antibody
  14. Positive screening test for antibodies
  15. Current or recent history (previous 12 months) of excessive use or abuse of alcohol
  16. Current evidence or history of abusing legal drugs or use of illegal drugs or substances
  17. Donation of 450 mL of blood within 8 weeks of the Screening Visit
  18. History of or intolerance to aerosol medications
  19. Participation in another drug study was received within 30 days prior to the Screening Visit
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Glycopyrrolate Inhalation Solution12.5μg

    Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution12.5μg

  • Experimental
    Glycopyrrolate Inhalation Solution 50μg

    Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 50μg

  • Experimental
    Glycopyrrolate Inhalation Solution 100μg

    Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 100μg

  • Experimental
    Glycopyrrolate Inhalation Solution 200μg

    Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 200μg

  • Experimental
    Glycopyrrolate Inhalation Solution 400μg

    Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily

    Drug: Glycopyrrolate Inhalation Solution 400μg

  • Placebo comparator
    Placebo 0.5mL

    Placebo 0.5mL via e-flow nebulizer, once daily

    Drug: Placebo 0.5mL

Interventions

  • DrugGlycopyrrolate Inhalation Solution12.5μg

    Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 50μg

    Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 100μg

    Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 200μg

    Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily

    Also known as: GIS

  • DrugGlycopyrrolate Inhalation Solution 400μg

    Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily

    Also known as: GIS

  • DrugPlacebo 0.5mL

    Placebo 0.5mL via eFlow, once daily

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Trough FEV1 (Change From Baseline)

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.

    Time frame: 24hr post dose

  2. Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.

    Time frame: 0-12h post dose

  3. Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.

    Time frame: 12-24h post dose

  4. Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)

    Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.

    Time frame: 0 to 24h

  5. Peak FEV1 (Change From Baseline and Percent Change)

    spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.

    Time frame: 0-4h post dose

Secondary outcomes

  1. Cmax; Maximum Observed Plasma Concentration

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hour

  2. Tmax; Time to Maximum Observed Plasma Concentration

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hours

  3. t1/2; Plasma Half-life

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hour

  4. AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hour

  5. AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity

    Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

    Time frame: 0 to 12 hour

  6. Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE

    AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment

    Time frame: Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)

  7. Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study

    Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.

    Time frame: 0-24 h

  8. Number of Clinically Significant Abnormal Laboratory Results Reported During the Study

    Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.

    Time frame: Day -14, Day 69

  9. Number of Subjects With Clinically Significant ECG Parameters Reported During the Study

    ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.

    Time frame: 0 to 24h

  10. Percentage of Subjects With Treatment Emergent AEs

    AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment

    Time frame: Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)

07

Results

Posted Mar 12, 2018

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started777777
Completed777777
Not completed000000
Washout Period 1
Participant flow — Washout Period 1
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started777777
Completed757776
Not completed020001
Withdrew: Adverse event020000
Withdrew: Protocol violation000001
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started757776
Completed757776
Not completed000000
Washout Period 2
Participant flow — Washout Period 2
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started757776
Completed747676
Not completed010100
Withdrew: Adverse event010000
Withdrew: Personal reasons000100
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started747676
Completed747676
Not completed000000
Washout Period 3
Participant flow — Washout Period 3
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started747676
Completed747676
Not completed000000
Treatment Period 4
Participant flow — Treatment Period 4
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started747676
Completed747676
Not completed000000
Washout Period 4
Participant flow — Washout Period 4
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started747676
Completed646676
Not completed101000
Withdrew: Adverse event101000
Treatment Period 5
Participant flow — Treatment Period 5
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started646676
Completed646676
Not completed000000
Washout Period 5
Participant flow — Washout Period 5
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started646676
Completed646676
Not completed000000
Treatment Period 6
Participant flow — Treatment Period 6
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started646676
Completed646676
Not completed000000
Wshout Period 6
Participant flow — Wshout Period 6
MilestoneTreatment Group 1Treatment Group 2Treatment Group 3Treatment Group 4Treatment Group 5Treatment Group 6
Started646676
Completed646676
Not completed000000

Outcome measures

PrimaryTrough FEV1 (Change From Baseline)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the mean of FEV1 values obtained at 23 hours 30 minutes and 24 hours post-dose of each Treatment Visit.

Time frame:
24hr post dose
Reported as:
Mean · liters
Trough FEV1 (Change From Baseline)
litersGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Trough FEV1 (Change From Baseline)-0.093 ± 0.11890.0114 ± 0.13080.0447 ± 0.15480.0542 ± 0.17790.0292 ± 0.1468-0.0612 ± 0.1233
Statistical analysis
  • Glycopyrrolate Inhalation Solution12.5μg vs Placebo 0.5mL · least squares mean · p = 0.1257 · Least squares mean: 0.033 · 95% CI -0.009 to 0.075
  • Glycopyrrolate Inhalation Solution 50μg vs Placebo 0.5mL · least squares mean · p = 0.0008 · Least squares mean: 0.072 · 95% CI 0.030 to 0.113
  • Glycopyrrolate Inhalation Solution 100μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.102 · 95% CI 0.061 to 0.144
  • Glycopyrrolate Inhalation Solution 200μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.108 · 95% CI 0.066 to 0.150
  • Glycopyrrolate Inhalation Solution 400μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.098 · 95% CI 0.056 to 0.140
PrimaryStandardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines.. The standardized actual FEV1 AUC(0-12) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-12) was also calculated similarly, using the change from pre-dose FEV1.

Time frame:
0-12h post dose
Reported as:
Mean · liters
Standardized FEV1AUC0-12 Area Under the FEV1 Curve From 0 to 12 Hours Post-dose ( Actual and Change From Baseline).
litersGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
actual standardized FEV1 AUC0_121.259 ± 0.4091.311 ± 0.4221.335 ± 0.3941.374 ± 0.3911.390 ± 0.4231.180 ± 0.427
change from baseline standardized FEV1 AUC0_120.055 ± 0.1130.126 ± 0.1120.136 ± 0.1340.184 ± 0.1340.170 ± 0.110-0.024 ± 0.095
Statistical analysis
  • Glycopyrrolate Inhalation Solution12.5μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.086 · 95% CI 0.050 to 0.123
  • Glycopyrrolate Inhalation Solution 50μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.151 · 95% CI 0.114 to 0.187
  • Glycopyrrolate Inhalation Solution 100μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.156 · 95% CI 0.120 to 0.193
  • Glycopyrrolate Inhalation Solution 200μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.202 · 95% CI 0.165 to 0.239
  • Glycopyrrolate Inhalation Solution 400μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.199 · 95% CI 0.162 to 0.235
PrimaryStandardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. The standardized actual FEV1 AUC(12-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(12-24) was also calculated similarly, using the change from pre-dose FEV1.

Time frame:
12-24h post dose
Reported as:
Mean · liters
Standardized FEV1AUC12-24 Area Under the FEV1 Curve From 12 to 24 Hours Post- Dose (Actual and Change From Baseline).
litersGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
acutal standardized FEV1 AUC0_121.165 ± 0.3771.203 ± 0.4041.227 ± 0.3691.253 ± 0.3461.259 ± 0.3961.123 ± 0.392
change from baseline standardized FEV1 AUC0_12-0.038 ± 0.1320.018 ± 0.1350.028 ± 0.1380.063 ± 0.1780.039 ± 0.135-0.082 ± 0.120
Statistical analysis
  • Glycopyrrolate Inhalation Solution12.5μg vs Placebo 0.5mL · least squares mean · p = 0.0028 · Least squares mean: 0.058 · 95% CI 0.021 to 0.095
  • Placebo 0.5mL · least squares mena · p = <0.0001 · Least squares mean: 0.100 · 95% CI 0.063 to 0.137
  • Glycopyrrolate Inhalation Solution 100μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.105 · 95% CI 0.068 to 0.142
  • Glycopyrrolate Inhalation Solution 200μg vs Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.135 · 95% CI 0.098 to 0.173
  • Placebo 0.5mL · least squares mean · p = <0.0001 · Least squares mean: 0.128 · 95% CI 0.091 to 0.166
PrimaryStandardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)

Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The standardized actual FEV1 AUC(0-24) was calculated using the trapezoidal rule divided by the actual hours from the first FEV1 to the last FEV1 in the interval. Standardized change from baseline FEV1 AUC(0-24) was also calculated similarly, using the change from pre-dose FEV1.

Time frame:
0 to 24h
Reported as:
Mean · liters
Standardized FEV1 AUC0-24 Area Under the FEV1 Curve From 0 to 24 Hours Post-dose (Actual and Change Baseline)
litersGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Actual standardized FEV1 AUC0_121.212 ± 0.3911.257 ± 0.4111.281 ± 0.3791.313 ± 0.3641.325 ± 0.4071.151 ± 0.408
change from baseline standardized FEV1 AUC0_120.009 ± 0.1140.072 ± 0.1150.082 ± 0.1280.123 ± 0.1460.105 ± 0.113-0.053 ± 0.102
PrimaryPeak FEV1 (Change From Baseline and Percent Change)

spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. . The peak FEV1 was defined as the highest post-dose FEV1 value within 4 hrs after the dose. Percent change from baseline was calculated as 100 times the difference of peak FEV1 minus baseline FEV1 divided by baseline FEV1.

Time frame:
0-4h post dose
Reported as:
Mean · liters
Peak FEV1 (Change From Baseline and Percent Change)
litersGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Change from baseline0.165 ± 0.1130.229 ± 0.1130.260 ± 0.1510.292 ± 0.1200.272 ± 0.1250.061 ± 0.102
percent change from baseline15.30 ± 11.3721.05 ± 11.8724.14 ± 20.6926.73 ± 12.5625.44 ± 15.105.24 ± 8275
SecondaryCmax; Maximum Observed Plasma Concentration

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hour
Reported as:
Geometric mean · pg/mL
Cmax; Maximum Observed Plasma Concentration
pg/mLGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μg
Cmax; Maximum Observed Plasma Concentration59.25 ± 78.4974.48 ± 62.24144.58 ± 52.53316.05 ± 48.35504.93 ± 55.67
SecondaryTmax; Time to Maximum Observed Plasma Concentration

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hours
Reported as:
Median · hours
Tmax; Time to Maximum Observed Plasma Concentration
hoursGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μg
Tmax; Time to Maximum Observed Plasma Concentration0.165 (0.150 to 0.180)0.320 (.0150 to 0.350)0.260 (0.150 to 0.330)0.275 (0.150 to 0.380)0.180 (0.150 to 0.320)
Secondaryt1/2; Plasma Half-life

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hour
Reported as:
Geometric mean · hours
t1/2; Plasma Half-life
hoursGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μg
t1/2; Plasma Half-life—0.8949 ± 2.37073.0137 ± 50.75573.1663 ± 45.48394.1238 ± 63.5353
SecondaryAUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hour
Reported as:
Geometric mean · pg.h/ml
AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.
pg.h/mlGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μg
AUC0-t; Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Drug Concentration.135.87 ± 209.2767.18 ± 143.22237.80 ± 98.45677.24 ± 66.341481.36 ± 82.17
SecondaryAUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity

Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr

Time frame:
0 to 12 hour
Reported as:
Geometric mean · pg.h/ml
AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity
pg.h/mlGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μg
AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity—246.84 ± 37.49634.65 ± 34.28772.59 ± 26.301367.76 ± 76.70
SecondaryNumber of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE

AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment

Time frame:
Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)
Reported as:
Number · participants
Number of Subjects Who Died, Number of Subjects With Treatment Emergent SAEs, Number of Subjects Who Discontinued Due to AE
participantsGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
subjects who died000000
subjects with treatment emergent SAEs001000
Subjects whodiscontinued due to an AE222000
subjects with treatment emergent AEs161417151314
SecondaryNumber of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study

Vital signs were measured at screening and at each Treatment Visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.

Time frame:
0-24 h
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study
ParticipantsGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study000000
SecondaryNumber of Clinically Significant Abnormal Laboratory Results Reported During the Study

Clinical safety lab parameters were collected at screening and at the post study assessment. Any laboratory values that were out of range of normal reference values were evaluated by the Investigators.

Time frame:
Day -14, Day 69
Reported as:
Number · number of events
Number of Clinically Significant Abnormal Laboratory Results Reported During the Study
number of eventsGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Number of Clinically Significant Abnormal Laboratory Results Reported During the Study000000
SecondaryNumber of Subjects With Clinically Significant ECG Parameters Reported During the Study

ECGs were recorded at screening and at each study treatment visit pre-dose (within 30 minutes prior to dose); post-dose at 30 minutes and 1, 2, 4, 8, 12 and 24 hours; and then at the post study assessment.

Time frame:
0 to 24h
Reported as:
Count of participants · Participants
Number of Subjects With Clinically Significant ECG Parameters Reported During the Study
ParticipantsGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Number of Subjects With Clinically Significant ECG Parameters Reported During the Study000000
SecondaryPercentage of Subjects With Treatment Emergent AEs

AE's are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment

Time frame:
Day 69 (includes dosing Day 1, washout Day 12, safety follow up Day 69)
Reported as:
Number · percentage of participants
Percentage of Subjects With Treatment Emergent AEs
percentage of participantsGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
Percentage of Subjects With Treatment Emergent AEs41.036.845.940.535.137.8

Adverse events

Collected over 0-69 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glycopyrrolate Inhalation Solution12.5μg—0/39 (0%)13/39 (33.3%)
Glycopyrrolate Inhalation Solution 50μg—0/38 (0%)9/38 (23.7%)
Glycopyrrolate Inhalation Solution 100μg—1/37 (2.7%)10/37 (27%)
Glycopyrrolate Inhalation Solution 200μg—0/37 (0%)10/37 (27%)
Glycopyrrolate Inhalation Solution 400μg—0/37 (0%)10/37 (27%)
Placebo 0.5mL—0/37 (0%)10/37 (27%)
Most frequent serious events
Most frequent serious events
EventGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
groin painGeneral disorders0/390/381/370/370/370/37
Most frequent other events
Most frequent other events
EventGlycopyrrolate Inhalation Solution12.5μgGlycopyrrolate Inhalation Solution 50μgGlycopyrrolate Inhalation Solution 100μgGlycopyrrolate Inhalation Solution 200μgGlycopyrrolate Inhalation Solution 400μgPlacebo 0.5mL
headacheNervous system disorders6/395/385/377/376/374/37
coughRespiratory, thoracic and mediastinal disorders3/392/385/373/373/375/37
dyspnoeaRespiratory, thoracic and mediastinal disorders3/392/381/371/371/372/37
skin injuryInjury, poisoning and procedural complications0/390/380/370/370/372/37
chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/391/380/370/370/370/37

Baseline characteristics

Intent to treat population same as safety population -not full analysis set

Age, Categorical
Age, Categorical(Participants)Total Participants
<=18 years0
Between 18 and 65 years29
>=65 years13
Age, Continuous
Age, Continuous(years)Total Participants
Mean62.0 ± 6.99
Sex: Female, Male
Sex: Female, Male(Participants)Total Participants
Female15
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total Participants
Hispanic or Latino0
Not Hispanic or Latino42
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White41
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Total Participants
United Kingdom42
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Leaker BR, Barnes PJ, Jones CR, Tutuncu A, Singh D. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2015 Mar;79(3):492-500. doi: 10.1111/bcp.12517. PubMed 25243340 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2018, 7 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Oct 28, 2016
Start
Jul 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Mar 12, 2018
Last update
Mar 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02948582
Responsible party
Sponsor
First posted
Oct 28, 2016
Start date
Jul 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Mar 12, 2018
Last update
Mar 12, 2018

Study contacts

Ahmet Tutuncu, MD, PhD
study chair · Elevation Pharmaceuticals, Inc., (now known as Sunovion Respriatory Developement Inc.)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion